Long-acting reversible contraception (LARC) with the intrauterine system with levonorgestrel (6 mcg/d): observational study on the acceptability, quality of life, and sexuality in Italian women

Neri, Manuela;Piras, Bruno;Paoletti, Anna Maria;Vallerino, Valerio;Corda, Valentina;Ronchetti, Camilla;Taccori, Valeria;Pilloni, Monica;Zedda, Pierina;Capobianco, Giampiero;Dessole, Salvatore;Melis, Gian Benedetto;Mais, Valerio

2018-01-01

---

Abstract

This observational study was conducted in healthy premenopausal women, who presented themselves for contraception with an intrauterine system (IUS) releasing LNG (6 mcg/d) (Jaydess®, Bayer, Germany) at the outpatient Family Planning Clinics of the Departments of Obstetrics and Gynaecology of the Universities of Cagliari and Sassari (CA/SS), University-Hospitals of CA/SS (Italy). After a screening visit, 31 women without contraindications to Jaydess® were included in the study. No difficulty in Jaydess® insertion (Ji) was found in 87% of subjects, with pelvic pain (PP) (visual analogic scale, VAS:5.33 ± 2.54) reported by 27/31 subjects at the Ji. Pelvic pain was reported by 17/31 subjects on the first day (VAS: 3.07 ± 3.1), 16/31 subjects on the second day (VAS:2.37 ± 2.71), and 11/31 subjects on the third day (VAS:1.18 ± 2.02) from Ji, with a significant (p  < .001) decrease in the intensity. the primary purposes of study were to evaluate whether a 12-month-treatment (12-m-t) with jaydess⮠interferes on either quality life (qol) or sexuality. did not modify qol sexuality 25 subjects who completed 12-m-t. throughout 12-m-t, pp, pregnancies found; menstrual blood loss was significantly (p < .0001) reduced, and intensity vas dysmenorrhea (#14 subjects) (p < .001) improved. < div>